Dubin Research & Consulting (DRC)’s Post

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be utilized to progress its lead product candidate, Chimeric Antigen Receptor T-cells (HEMO-CAR-T), into human trials following the lifting of a clinical hold. The HEMO-CAR-T therapy is focused on treating relapsed and refractory acute myeloid leukaemia. Despite the challenging market conditions, particularly for biotech firms, Sandler said HemoGenyx successfully secured the necessary funds. He highlighted the company's efficiency and ability to progress with minimal funds, contrasting the struggles faced by other micro-cap companies in raising capital. Watch at #Proactive #ProactiveInvestors #LSE #OTC #HEMO #HOPHF#leukaemia #biotech http://ow.ly/kY1U105lyyS

Ligand’s Captisol technology platform has helped optimize the solubility and stability of drugs for some of the world’s leading biopharmaceutical companies including Merck Pfizer Amgen and Gilead Sciences. Today there are more than 15 Captisol-enabled™ products approved worldwide. The leaders of our Captisol team, Drs. Vince Antle and James Pipkin, recently sat down with Lawrence Business Magazine to discuss how this unique technology has changed how drugs are developed and formulated. Read the article here: https://bit.ly/4bRjJtv

US companies are leading the race for next-generation therapeutics (NGT) championship. However, Europe is catching up. In the infographic, we depicted a pipeline analysis of the biggest pharmaceutical companies in the world. R&D intensity is the R&D expenditure as share of the total revenue. The bubble size represents the NGTs in relation to all entities in the pipeline. Find out more about the approach for mastering next-generation therapeutics in the Porsche Consulting Strategy Paper “Pharma’s transformation towards next-generation therapeutics”: https://lnkd.in/eeUTebZq #Pharma #NGT #NextGenerationTherapeutics #CellAndGeneTherapy #advancedtherapymedicinalproducts

fast cell line engineering that is super flexible. this is what our LandingPad Cell Lines are made for. I will summarize some results in my next posts

Acute Lung Injury Market to Register Stunning Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Asklepion Pharmaceuticals, Edesa Biotech, Direct Biologics, AstraZeneca, Windtree Therapeutics, Lee Pharmaceutical https://lnkd.in/eb6rDyea #marketanalysis #marketresearch #marketresearchreports #businessintelligence

https://lnkd.in/e6mJGyHD Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up fast-growing biotechs to replenish their pipelines. A purchase by the Swiss drug company of South San Francisco-based Cytokinetics, which has a market value of more than $10 billion, could be completed as soon as this week, according to people familiar with the situation. Cytokinetics is focused on so-called muscle activators and inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised, according to its website. Cytokinetics’ #cardiomyopathy therapy would complement drugs like the cholesterol treatment called #Leqvio that Novartis acquired as part of a nearly $10 billion deal for The Medicines Company in 2020. #BigPharma

BioPharmCatalyst currently has 56 upcoming events within the PDUFA, PDUFA Priority Review, and/or Advisory Committee categories over the next several years. Check out our PDUFA calendar to stay on top of all of these major regulatory decisions. #biotech #biotechinvesting #fdacalendar #regulatory #biotechstocks #pharmainvesting #pdufa #catalyst #betherewhenithappens #fasterscience

Check out our new VIDEO: https://lnkd.in/dBjixNmN about Vertex Pharmaceuticals and it's stock price! From pioneering cystic fibrosis treatments to their newest gene-editing therapy Casgevy, find out why Vertex might be the hidden gem in biotech. #vertex #pharmaceuticals #stockstowatch